[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339448-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339448-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","overexpression-of-col11a1-confers-tamoxifen-resistance-in-breast-cancer","Overexpression of COL11A1 confers tamoxifen resistance in breast cancer","","Breast cancer frequently benefits from endocrine therapy such as tamoxifen, yet drug resistance undermines treatment by driving recurrence and poor outcomes. This study reports that high collagen type XI alpha 1 (COL11A1) expression is linked to inferior therapeutic response and prognosis in tamoxifen-treated patients. MCF-7/COL11A1 and T47D/COL11A1 models show increased resistance to 4-OHT, while COL11A1 depletion sensitizes cells in vitro and in vivo. Mechanistically, COL11A1 upregulates estrogen receptor α (ERα) and downstream targets, suggesting that targeting COL11A1 may reverse endocrine resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/overexpression-of-col11a1-confers-tamoxifen-resistance-in-breast-cancer/339448/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/overexpression-of-col11a1-confers-tamoxifen-resistance-in-breast-cancer/339448.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How is COL11A1 related to tamoxifen response in breast cancer?","Question",{"text":63,"@type":64},"High COL11A1 expression is associated with poor therapeutic response and prognosis in breast cancer patients treated with tamoxifen.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What happens to tamoxifen sensitivity when COL11A1 is knocked down?",{"text":68,"@type":64},"COL11A1 depletion markedly sensitizes tamoxifen-resistant cells to 4-OHT in both vitro and in vivo settings.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism is proposed for COL11A1-driven tamoxifen resistance?",{"text":72,"@type":64},"The study suggests increased COL11A1 elevates ERα expression and downstream target genes, and COL11A1 knockdown decreases ERα signaling, reversing resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339448,1790788698,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","npj | breast cancer Article  \nPublished in partnership with the Breast Cancer Research Foundation  \n[https://doi.org/10.1038/s41523-024-00645-3](https://doi.org/10.1038/s41523-024-00645-3)  \nOverexpression of COL11A1 confers tamoxifen resistance in breast cancer  \n Check for updates  \nHigh level of  \n\n| Chengxiao Fu1,2,6, Shan Duan3,6, Xiaoming Zhou4, Yingcai Meng5 & Xisha Chen 1  |  |\n| --- | --- |\n| Breast cancer is the most commonly diagnosed malignancy and beneﬁts from endocrine agents such as tamoxifen. However, the development of drug resistance in cancerous cells often leads to recurrence, thus limiting the therapeutic beneﬁt. Identiﬁcation of potential biomarkers that can predict response to tamoxifen and recognize patients who will clinically beneﬁt from this therapy is urgently needed. In this study, we report that high collagen type XI alpha 1 (COL11A1) expression was associated with poor therapeutic response and prognosis in breast cancer patients treated with tamoxifen. To conﬁrm the role of COL11A1 in the development of tamoxifen resistance, we established MCF-7/COL11A1 and T47D/COL11A1 cell lines, which stably expressed COL11A1 . Compared with parental MCF-7 and T47D, MCF-7/COL11A1 and T47D/COL11A1 cells were more resistant to 4-OHT-induced growth inhibition. Moreover, the level of COL11A1 expression was upregulated in tamoxifen-resistant MCF-7/TamR and T47D/TamR cell lines, and depletion of COL11A1markedly sensitized the cells to4-OHTin vitro and in vivo. Interestingly, the level of estrogen receptor α (ERα) expression was elevated, probably due to the increased COL11A1 in TamR cells. In addition, knockdown of COL11A1 decreased the expression of ERα and its downstream target genes. Overall, our ﬁndings suggest that overexpressed COL11A1 contributes to tamoxifen resistance, and targeting COL11A1 holds great promise for reversing endocrine resistance. |  |\n| Breast cancer has come to be the most commonly diagnosed cancer worldwide and remains the leading cause of cancer death in women1. Approximately 70% of breast cancers present as ERα positive (+) and respond to anti-estrogen therapy such as tamoxifen, a commonly prescribed endocrine agent that exerts anti-cancer effect via competing with estrogen for binding to ERα2. Despite the markedly improvement in survival rates of breast cancer patients, the development of drug resistance presents a major challenge in the clinic, for which severely limited the efﬁcacy of endocrine therapy, leading to breast cancer recurrence and mortality3.\u003Cbr>Thus far, there have been accumulating studies focused on elucidating the mechanisms underlying the tamoxifen resistance and several major pathways have been recognized to be involved in this process. Altered or aberrant ER transcriptional activity is one of the mechanisms that mediate tamoxifen resistance and promote tumor progression4,5. On the other hand, activation of receptor tyrosine kinases has been observed in endocrine | resistant tumors and been reported to induce tamoxifen resistance6–9. In addition, cross-talk between alternative signaling pathways involving cell proliferation and survival has also been demonstrated to promote tamoxifen resistance10–12. In view of the complexity of mechanisms underlie resistance, it is imperative to identify potential molecular markers associated with therapeutic response.\u003Cbr>Collagen type XI alpha1(COL11A1), oneofthree alpha chains oftype XI collagen, belongs to the collagen family, the main component of extracellular matrix (ECM). Although it was initially reported to regulate bone development and collagen ﬁber assembly13, recent studies have recognized COL11A1 plays a crucial role in multiple types of cancer14, 15. COL11A1 is frequently upregulated and correlated with aggressive phenotype and poor prognosis in ovarian, colorectal and pancreatic cancers16–18.\u003Cbr>COL11A1 promotes tumor cell proliferation, migration and metastasis19. Further research found that COL11A1mediates resistanc","cbCaimJnQdwHqDpe","https://ap.wps.com/l/cbCaimJnQdwHqDpe","pdf",2041596,"English","# Results\n## COL11A1 is upregulated in ER-positive breast cancer and correlates with poor endocrine therapeutic benefits","[{\"question\":\"How is COL11A1 related to tamoxifen response in breast cancer?\",\"answer\":\"High COL11A1 expression is associated with poor therapeutic response and prognosis in breast cancer patients treated with tamoxifen.\"},{\"question\":\"What happens to tamoxifen sensitivity when COL11A1 is knocked down?\",\"answer\":\"COL11A1 depletion markedly sensitizes tamoxifen-resistant cells to 4-OHT in both vitro and in vivo settings.\"},{\"question\":\"What mechanism is proposed for COL11A1-driven tamoxifen resistance?\",\"answer\":\"The study suggests increased COL11A1 elevates ERα expression and downstream target genes, and COL11A1 knockdown decreases ERα signaling, reversing resistance.\"}]","Overexpression of COL11A1 confers tamoxifen resistance in breast cancer | PDF",1790030341,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f0f86a9f1e63ca76831ac228b81ab95.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d96432a04fd1de5a7bde1c59bb39e402.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95246d4b85c166dbb9a12ab43a4c82c9.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dafcea178d04e4a5167e9f2e6fd5e718.webp",980,1301]